Literature DB >> 27280799

Treatment With Human Wharton's Jelly-Derived Mesenchymal Stem Cells Attenuates Sepsis-Induced Kidney Injury, Liver Injury, and Endothelial Dysfunction.

José M Cóndor1, Camila E Rodrigues2, Roberto de Sousa Moreira2, Daniele Canale2, Rildo A Volpini2, Maria H M Shimizu2, Niels O S Camara3, Irene de L Noronha2, Lúcia Andrade4.   

Abstract

UNLABELLED: : The pathophysiology of sepsis involves complex cytokine and inflammatory mediator networks. Downregulation of endothelial nitric oxide synthase contributes to sepsis-induced endothelial dysfunction. Human Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) are known to reduce expression of proinflammatory cytokines and markers of apoptosis. We hypothesized that treatment with WJ-MSCs would protect renal, hepatic, and endothelial function in a cecal ligation and puncture (CLP) model of sepsis in rats. Rats were randomly divided into three groups: sham-operated rats; rats submitted to CLP and left untreated; and rats submitted to CLP and intraperitoneally injected, 6 hours later, with 1 × 10(6) WJ-MSCs. The glomerular filtration rate (GFR) was measured at 6 and 24 hours after CLP or sham surgery. All other studies were conducted at 24 hours after CLP or sham surgery. By 6 hours, GFR had decreased in the CLP rats. At 24 hours, Klotho renal expression significantly decreased. Treatment with WJ-MSCs improved the GFR; improved tubular function; decreased the CD68-positive cell count; decreased the fractional interstitial area; decreased expression of nuclear factor κB and of cytokines; increased expression of eNOS, vascular endothelial growth factor, and Klotho; attenuated renal apoptosis; ameliorated hepatic function; increased glycogen deposition in the liver; and improved survival. Sepsis-induced acute kidney injury is a state of Klotho deficiency, which WJ-MSCs can attenuate. Klotho protein expression was higher in WJ-MSCs than in human adipose-derived MSCs. Because WJ-MSCs preserve renal and hepatic function, they might play a protective role in sepsis. SIGNIFICANCE: Sepsis is the leading cause of death in intensive care units. Although many different treatments for sepsis have been tested, sepsis-related mortality rates remain high. It was hypothesized in this study that treatment with human Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) would protect renal, hepatic, and endothelial function in a model of sepsis in rats. Treatment with WJ-MSCs improved the glomerular filtration rate, improved tubular function, decreased expression of nuclear factor κB and of cytokines, increased expression of eNOS and of Klotho, attenuated renal apoptosis, and improved survival. Sepsis-induced acute kidney injury is a state of Klotho deficiency, which WJ-MSCs can attenuate. ©AlphaMed Press.

Entities:  

Keywords:  Apoptosis; Endothelium-derived factors; Interleukins; Kidney injury; Liver injury; Wharton’s jelly-derived mesenchymal stem cells

Mesh:

Substances:

Year:  2016        PMID: 27280799      PMCID: PMC4954445          DOI: 10.5966/sctm.2015-0138

Source DB:  PubMed          Journal:  Stem Cells Transl Med        ISSN: 2157-6564            Impact factor:   6.940


  39 in total

Review 1.  Emerging drugs for the treatment of sepsis.

Authors:  Antigone Kotsaki; Evangelos J Giamarellos-Bourboulis
Journal:  Expert Opin Emerg Drugs       Date:  2012-07-11       Impact factor: 4.191

2.  Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice.

Authors:  Jianguo Xu; Charles R Woods; Ana L Mora; Robert Joodi; Kenneth L Brigham; Smita Iyer; Mauricio Rojas
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2007-04-06       Impact factor: 5.464

3.  Multipotential mesenchymal stem cells are mobilized into peripheral blood by hypoxia.

Authors:  Gaël Y Rochefort; Bruno Delorme; Adriana Lopez; Olivier Hérault; Pierre Bonnet; Pierre Charbord; Véronique Eder; Jorge Domenech
Journal:  Stem Cells       Date:  2006-06-15       Impact factor: 6.277

4.  Cells derived from young bone marrow alleviate renal aging.

Authors:  Hai-Chun Yang; Michele Rossini; Li-Jun Ma; Yiqin Zuo; Ji Ma; Agnes B Fogo
Journal:  J Am Soc Nephrol       Date:  2011-09-30       Impact factor: 10.121

Review 5.  Discarded Wharton jelly of the human umbilical cord: a viable source for mesenchymal stromal cells.

Authors:  Nate Watson; Ryan Divers; Roshan Kedar; Ankur Mehindru; Anuj Mehindru; Mia C Borlongan; Cesar V Borlongan
Journal:  Cytotherapy       Date:  2014-10-18       Impact factor: 5.414

6.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

7.  Effects of continuous erythropoietin receptor activator in sepsis-induced acute kidney injury and multi-organ dysfunction.

Authors:  Camila E Rodrigues; Talita R Sanches; Rildo A Volpini; Maria H M Shimizu; Patrícia S Kuriki; Niels O S Camara; Antonio C Seguro; Lúcia Andrade
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

8.  Role of HMGB1 in apoptosis-mediated sepsis lethality.

Authors:  Shixin Qin; Haichao Wang; Renqi Yuan; Hui Li; Mahendar Ochani; Kanta Ochani; Mauricio Rosas-Ballina; Chris J Czura; Jared M Huston; Ed Miller; Xinchun Lin; Barbara Sherry; Anjali Kumar; Greg Larosa; Walter Newman; Kevin J Tracey; Huan Yang
Journal:  J Exp Med       Date:  2006-07-03       Impact factor: 14.307

9.  A comparison of adipose and bone marrow-derived mesenchymal stromal cell secreted factors in the treatment of systemic inflammation.

Authors:  Jessica S Elman; Matthew Li; Fangjing Wang; Jeffrey M Gimble; Biju Parekkadan
Journal:  J Inflamm (Lond)       Date:  2014-01-07       Impact factor: 4.981

10.  TNF-mediated damage to glomerular endothelium is an important determinant of acute kidney injury in sepsis.

Authors:  Chang Xu; Anthony Chang; Bradley K Hack; Michael T Eadon; Seth L Alper; Patrick N Cunningham
Journal:  Kidney Int       Date:  2013-07-31       Impact factor: 10.612

View more
  28 in total

Review 1.  Cell therapy in acute respiratory distress syndrome.

Authors:  Shahd Horie; Hector Esteban Gonzalez; John G Laffey; Claire H Masterson
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

2.  Antibacterial Fusion Protein BPI21/LL-37 Modification Enhances the Therapeutic Efficacy of hUC-MSCs in Sepsis.

Authors:  Zhan Li; Yuqing Song; Peisong Yuan; Wei Guo; Xueting Hu; Wei Xing; Luoquan Ao; Yan Tan; Xiaofeng Wu; Xiang Ao; Xiao He; Dongpo Jiang; Huaping Liang; Xiang Xu
Journal:  Mol Ther       Date:  2020-05-15       Impact factor: 11.454

Review 3.  Cell therapy for the treatment of sepsis and acute respiratory distress syndrome.

Authors:  Raquel Guillamat-Prats; Marta Camprubí-Rimblas; Josep Bringué; Neus Tantinyà; Antonio Artigas
Journal:  Ann Transl Med       Date:  2017-11

Review 4.  Exploring the roles of MSCs in infections: focus on bacterial diseases.

Authors:  Pasquale Marrazzo; Annunziata Nancy Crupi; Francesco Alviano; Laura Teodori; Laura Bonsi
Journal:  J Mol Med (Berl)       Date:  2019-02-07       Impact factor: 4.599

5.  Possible Underlying Mechanisms for the Renoprotective Effect of Retinoic Acid-Pretreated Wharton's Jelly Mesenchymal Stem Cells against Renal Ischemia/Reperfusion Injury.

Authors:  Mai Barakat; Abdelaziz M Hussein; Mohamed F Salama; Amira Awadalla; Nashwa Barakat; Mohamed Serria; Mohamed El-Shafey; Mohamed El-Sherbiny; Mohamed A El Adl
Journal:  Cells       Date:  2022-06-22       Impact factor: 7.666

6.  Using the Cecal Ligation and Puncture Model of Sepsis to Induce Rats to Multiple Organ Dysfunction.

Authors:  Jose Manuel Cóndor Capcha; Roberto S Moreira; Camila E Rodrigues; Marcelo A D Silveira; Lucia Andrade; Samirah A Gomes
Journal:  Bio Protoc       Date:  2021-04-05

7.  Optimal timing of renal replacement therapy for favourable outcome in patients of acute renal failure following cardiac surgery.

Authors:  Shanshank Tripathi; Shantanu Pande; Pulkit Malhotra; Supaksh Mahindru; Ankit Thukral; Ankush Singh Kotwal; Gauranga Majumdar; Surendra Kumar Agarwal; Amit Gupta
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2019-09-05

8.  Therapeutic Potential of Extracellular Vesicles for Sepsis Treatment.

Authors:  Stephanie M Kronstadt; Alex E Pottash; Daniel Levy; Sheng Wang; Wei Chao; Steven M Jay
Journal:  Adv Ther (Weinh)       Date:  2021-04-29

Review 9.  Concise Review: Mesenchymal Stromal Cell-Based Approaches for the Treatment of Acute Respiratory Distress and Sepsis Syndromes.

Authors:  Christian L Johnson; Yorick Soeder; Marc H Dahlke
Journal:  Stem Cells Transl Med       Date:  2017-01-09       Impact factor: 6.940

Review 10.  Mesenchymal Stem Cells in Sepsis and Associated Organ Dysfunction: A Promising Future or Blind Alley?

Authors:  Jan Horák; Lukáš Nalos; Vendula Martínková; Jan Beneš; Milan Štengl; Martin Matějovič
Journal:  Stem Cells Int       Date:  2017-09-14       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.